C-TACE与D-TACE治疗原发性肝癌患者疗效与安全性比较研究*

doi:10.3969/j.issn.1672-5069.2026.05.025

摘要/Abstract

摘要： 目的比较研究传统的经导管动脉化疗栓塞(C-TACE与载药微球行肝动脉栓塞(D-TACE)治疗肝细胞癌患者的疗效与安全性。方法 2020年1月～2023年2月我院收治的HCC患者104例,其中56例观察组接受D-TACE治疗,48例对照组接受C-TACE治疗,随访2年。常规检测血清甲胎蛋白(AFP)和异常凝血酶原(PIVKA-II)水平。结果观察组短期疾病控制率显著高于对照组(85.7%对66.7%,P＜0.05);治疗后,观察组血清AFP和PIVKA-II水平分别为(90.4±16.7)μg/L和(361.0±41.9)μg/L,均显著低于对照组【分别为(154.1±20.5)μg/L和(421.4±48.7)μg/L,P＜0.05】;观察组恶心、白细胞计数下降和血清转氨酶水平升高占比分别为7.1%、16.1%和12.5%,均显著低于对照组的22.9%、35.4%和31.3%(P＜0.05);观察组1年和2年生存率分别为84.9%(45/53)和69.8%(37/53),均显著高于对照组的68.3%(28/41,P<0.05)和51.2%(21/41,P<0.05)。结论采取D-TACE治疗HCC患者更有助于提高疾病控制率,降低术后不良反应发生率,提高生存率。

关键词: 肝细胞癌, 载药微球行肝动脉栓塞, 治疗, 生存率

Abstract: Objective The aim of this clinical trial was to compare efficacy of drug-eluting beads transarterial chemoembolization (D-TACE) and conventional transarterial chemoembolization (C-TACE) in the treatment of patients with hepatocellular carcinoma (HCC). Methods A total of 104 patients with HCC were encountered in our hospital between January 2020 and February 2023, were assigned to receive D-TACE in 56 cases, or to receive C-TACE in 48 cases, and all were followed-up for two years. Serum alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels were routinely detected. Results A comparatively higher disease control rate (DCR) was observed in D-TACE group than in C-TACE group (85.7% vs. 66.7%, respectively, P＜0.05); after treatment, serum AFP and PIVKA-II levels in D-TACE group were (90.4±16.7)μg/L and (361.0±41.9)μg/L, both much lower than [(154.1±20.5)μg/L and (421.4±48.7)μg/L, respectively, P＜0.05] in C-TACE group; incidence of adverse effects, such as nausea, granulocytopenia and serum ALT level elevation in D-TACE group were 7.1%, 16.1% and 12.5%, all much lower than 22.9%, 35.4% and 31.3%(P＜0.05) in C-TACE group; one- and two-year survival rates in D-TACE group were 84.9%(45/53) and 69.8%(37/53), both much higher than 68.3%(28/41, P<0.05) and 51.2%(21/41, P<0.05) in C-TACE group. Conclusion D-TACE therapy is efficacious in treatment of patients with HCC, which might improve disease control rate, reduce postoperative adverse reactions, and prolong overall survival.

Key words: Hepatoma, Drug-eluting beads transarterial chemoembolization, Therapy, Survival

吴红, 沈兰超, 姜正伟, 吕春, 蒋培莉. C-TACE与D-TACE治疗原发性肝癌患者疗效与安全性比较研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 737-740.

Wu Hong, Shen Lanchao, Jiang Zhengwei, et al. Comparative study of drug-eluting beads and conventional transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2026, 29(5): 737-740.

参考文献

[1] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2021,71(3):209-249.
[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin,2024,74(3):229-263.
[3] 吕然,刘琛志. CalliSpheres载药微球TACE序贯微波消融治疗单发直径＞5 cm原发性老年肝癌的临床研究. 中华肿瘤防治杂志,2022,29(15):1136-1142.
[4] 韩大千,李浩,王满周,等. 载药微球的TACE与碘化油乳剂的TACE对肝纤维化的影响. 中华肝胆外科杂志,2024,30(10):738-743.
[5] 王楠,薛国亮,徐静雯,等. 微波消融在载药微球经肝动脉化疗栓塞术联合靶向和免疫治疗进展期原发性肝癌中的应用. 中华肿瘤防治杂志,2023,30(14):865-870.
[6] 叶禾清,李杰,张玉元,等. 载药微球化疗栓塞联合多纳非尼及PD-1治疗中晚期大肝癌的疗效分析. 中华介入放射学电子杂志,2024,12(3):212-216.
[7] Lu H, Zheng C, Liang B, et al. Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study. Medicine (Baltimore), 2023,102(40): e35433.
[8] Huang J X, Zhang W H, Wu Y M, et al. A study on overcomingpost-TACE drug resistance in HCC based on controllable oxygen release-magnetic hyperthermia therapy. Adv Healthc Mater,2024,13(32):e2402253.
[9] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版). 中华消化外科杂志,2020,19(1):1-20.
[10] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer,2009,45(2):228-247.
[11] 李臻,叶书文,谢炳灿,等. 不同粒径载药微球化学治疗栓塞治疗肝细胞癌的疗效分析. 中华肝脏病杂志,2022,30(6):612-617.
[12] 田鹏程,倪管崟,詹一,等. 球囊闭塞经导管动脉化疗栓塞治疗肝细胞癌的研究进展. 中华放射学杂志,2024,58(2):233-237.
[13] 雒夏,刘帅伟,海龙,等. 传统TACE与DEB-TACE治疗不可切除肝细胞癌患者的短期疗效和安全性比较. 中华肝胆外科杂志,2023,29(3):165-169.
[14] 董卉妍,张磊,缪冬镠,等. 伊达比星经动脉化疗栓塞介入治疗肝细胞癌研究进展. 中华医学杂志,2023,103(11):853-857.
[15] Zhang W, Wu L, Chen L, et al. The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus. Sci Rep, 2022,12(1):5725.
[16] Lyu Y F, Deng Z Q, Bi Q C, et al. Intratumoral Pi deprivation benefits chemoembolization therapy via increased accumulation of intracellular doxorubicin. Drug Deliv,2022,29(1):1743-1753.
[17] 王秀香,李海霞,李辉,等. DEB-TACE序贯微波消融术治疗原发性大肝癌患者临床疗效研究. 实用肝脏病杂志,2024,27(2):283-286.
[18] Mendez R A, van der Holt B, Willemssen F, et al. Transarterial chemoembolization withdrug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY Trial). Int J Radiat Oncol Biol Phys,2023,117(1):45-52.
[19] Wang Z Y, Xie C F, Feng K L, et al. Drug-eluting beads versus conventional transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore),2023,102(34):e34527.
[20] Liu Y, Zhou B, Tang W, et al. Preoperative transarterial chemoembolization with drug-eluting beads (DEB-TACE) in patients undergoing conversional hepatectomy: a propensity-score matching analysis.Eur Radiol,2023,33(2):1022-1030.
[21] 刘公攀,陈涛,丁志刚,等. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究. 实用肝脏病杂志,2023,26(6):879-882.
[22] Yang H, Qiu G P, Liu J, et al. Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma. World J Gastrointest Oncol,2024,16(11):4392-4401.
[23] Ikeda M, Arai Y, Inaba Y, et al. Conventional or drug-eluting beads, randomized controlled study of chemoembolization for hepatocellular carcinoma: JIVROSG-1302. Liver Cancer,2022,11(5):440-450.
[24] Ishikawa T, Imai M, Sato R, et al. Prognostic value of TACE with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with liver metastases from unresectable colorectal cancer. Anticancer Res,2023,43(8):3647-3651.
[25] Dhondt E, Lambert B, Hermie L, et al. (90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology,2022,303(3):699-710.
[26] Lu H, Liang B, Zheng C, et al. Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma. BMC Cancer,2024,24(1):1422.
[27] Ye T, Shao S H, Ji K, et al. Evaluation of short-term effects of drug-loaded microspheres and traditional transcatheter arterial chemoembolization in the treatment of advanced liver cancer. World J Gastrointest Oncol,2022,14(12):2367-2379.
[28] Zhao J, Wang J, Lu Y, et al. Neoadjuvant drug-eluting bead transarterial chemoembolization and tislelizumab therapy for resectable or borderline resectable hepatocellular carcinoma: A propensity score matching analysis. Eur J Surg Oncol,2023,49(12):107106.
[29] Ren Y, Sun B, Zhu L, et al. Drug-eluting bead transarterial chemoembolization combined with apatinib/camrelizumab for the treatment of advanced hepatocellular carcinoma with hepatic arterioportal shunts. Br J Radiol,2024,97(1164):1925-1930.

C-TACE与D-TACE治疗原发性肝癌患者疗效与安全性比较研究^*

Comparative study of drug-eluting beads and conventional transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王佳颖, 张濛销, 汤善宏. 慢性肝病患者肝自主神经系统病理生理作用及其机制研究进展[J]. 实用肝脏病杂志, 2026, 29(5): 645-648.
[2]	高原, 张爱兰, 林丽泉, 程小桂. 应用富马酸丙酚替诺福韦和富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2026, 29(5): 661-664.
[3]	李甜甜, 吴岩. GLP-1受体激动剂治疗2型糖尿病合并非酒精性脂肪性肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 673-676.
[4]	刘德军, 刘婧, 袁翊. 自身免疫性肝炎患者血清AAPR、LECT2和IL-21水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2026, 29(5): 677-680.
[5]	赵先群, 闫斌斌, 李德洋, 田春阳, 张向东. 原发性胆汁性胆管炎患者临床特征、自身抗体特点和预后分析^*[J]. 实用肝脏病杂志, 2026, 29(5): 685-688.
[6]	陈丽虹, 刘银辉, 高梅芳, 李品娣, 吴伟新, 张玮, 李洪昌. 肝病专用型肠内营养制剂治疗失代偿期乙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 705-708.
[7]	茹秀峰, 秦琳, 董小平, 李振平, 何锦来, 胡永辉. 脾动脉高选择性插管部分脾栓塞术治疗肝炎肝硬化并发脾功能亢进症患者临床疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 713-716.
[8]	冯丹丹, 刘子涵, 郝苗, 苟国娥, 党双锁. TACE联合仑伐替尼和卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效和安全性研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 721-724.
[9]	周中华, 李东惠, 宾盼, 武海洲, 沈海洋, 邢新博, 李天然. 肝细胞癌患者肝脏MSCT灌注成像参数判断肿瘤微血管密度意义探讨^*[J]. 实用肝脏病杂志, 2026, 29(5): 725-728.
[10]	朱贺, 李瑶姬, 王锐, 沈志纲. 信迪利单抗联合仑伐替尼治疗中晚期原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 729-732.
[11]	张莉, 杨均铖, 王佳, 杨国栋, 毛欢, 罗云蔓. 增强CT扫描评估TACE术治疗原发性肝癌患者效果研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 733-736.
[12]	梁蓁, 李瑶, 王莹. 超声引导下三种不同微创方法治疗单纯性肝囊肿患者疗效比较研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 749-752.
[13]	刘燕, 周祥, 钟玲. 超声引导下经皮穿刺置管引流治疗化脓性肝脓肿患者疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 753-756.
[14]	祝平, 朱佳, 李晓飞, 魏源, 卢西雅. 内镜下鼻胆管引流联合ERCP/EST治疗胆总管结石合并中重度急性胆管炎患者疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 773-776.
[15]	韩博强, 杨林, 张成, 周党军, 赵宝国, 李文翰. 急性梗阻性化脓性胆管炎患者病原菌分布及ERCP治疗疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(5): 777-780.